Equity Overview
Price & Market Data
Price: $0.719
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $1,529,521
Volume: 0
Performance Metrics
1 Week: -0.14%
1 Month: -25.17%
3 Months: -73.17%
6 Months: -64.23%
1 Year: -81.78%
YTD: -60.92%
Company Details
Employees: 2
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is based in Houston, Texas.